Novartis: anti-migraine drug Aimovig proves its superiority

(CercleFinance.com) - Novartis announced on Monday that its Phase IV comparative clinical trial between its migraine treatment Aimovig and the anti-epileptic topiramate has met its primary and secondary endpoints for superiority.


The study showed that the drug was safer and more effective in patients with episodic and chronic migraine attacks, with a lower tendency to discontinue treatment over a 24-week period, the Swiss pharmaceutical group said.

In particular, Aimovig has enabled a greater proportion of patients to achieve a 50% reduction in their monthly number of migraine days (MMD), Novartis explained.


Copyright (c) 2020 CercleFinance.com. All rights reserved.